Secretary of Defense Pete Hegseth has ordered mandatory annual testosterone deficiency screening for all U.S. service members over age 30, under a finalized Defense Department memorandum published July 15, 2026. The policy, formally titled "Health and Human Performance Optimization to Enhance Military Readiness" and bearing document identifier OSD004430-26, also makes the screening available on a voluntary basis to service members under 30. Hegseth announced the program in a video, and the memorandum is marked "RES FINAL," indicating it is a final resolution document (Defense.gov).

The New York Times reported on July 15 that the screenings will also include women, broadening the policy beyond male service members (The Verge). If a deficiency is identified, service members may opt into testosterone replacement therapy (TRT) but are not required to accept it.

Testosterone is a hormone that plays a key role in muscle mass, energy, and overall health in both men and women. The clinical threshold the policy hinges on is well established. Hypogonadism, the medical term for testosterone deficiency, is defined as a total testosterone level under 300 ng/dL (nanograms per deciliter, a standard way to measure hormone levels in the blood). According to the Endocrine Society, the condition affects roughly 35% of men older than 45 and between 30% and 50% of men with type 2 diabetes or obesity (Endocrine Society). After age 30, male testosterone levels decline at an average rate of about 1% per year.

Those age-related dynamics intersect directly with the military's career timeline. Active duty in most branches of the U.S. military ends around age 42, meaning the mandatory screening population covers the second half of a typical service member's career. The policy also lands alongside existing body-composition requirements: service members must already meet strict body fat limits. In January 2026, the Department of Defense issued "Additional Guidance on Military Fitness Standards," implementing waist-to-height ratio (WHtR) measurements effective January 1, 2026, as part of its body-composition framework (Defense.gov).

The broader backdrop is a decades-long decline in male testosterone and fertility metrics. Average testosterone levels in men have halved over the last 50 years, according to scientists reported by The Guardian (The Guardian). Sperm count and quality have also declined compared to previous generations. On the clinical demand side, U.S. testosterone prescriptions rose from under 1 million in 2000 to 12 million by 2025 (NYT Magazine). The policy, in that context, institutionalizes at the federal level a hormone metric that has increasingly entered consumer medicine, men's health discourse, and the direct-to-consumer wellness market.

The broader context here is the gap between what the Pentagon is mandating versus what it is merely offering. The mandatory component is the screening, not treatment. Service members found deficient can decline TRT. That distinction matters because testosterone optimization, however clinically valid for diagnosed hypogonadism, carries its own risk profile, and the military's chain-of-command structure introduces questions about how voluntary opt-in functions in practice when the screening is itself compulsory. Think of it like a required physical exam: the military can order the test, but a service member's decision to take medication afterward is, at least on paper, their own. The inclusion of women in the screening protocol, as reported by the Times, adds another dimension: while hypogonadism is most commonly discussed in male populations, testosterone deficiency in women is a recognized but less frequently diagnosed condition, and the military has not publicly detailed the clinical thresholds or treatment pathways that would apply.

This is also not the Defense Department's first recent move into metabolic and hormonal monitoring. The January 2026 WHtR guidance already shifted body-composition assessment toward a ratio-based metric. The testosterone screening memorandum extends that trajectory from body composition into endocrine function, framing both as readiness optimization rather than purely clinical care. The memorandum's title, with its emphasis on "human performance optimization," makes that framing explicit.

For the technology and health-data communities, the policy raises practical questions about implementation at scale. Annual testosterone screening across the over-30 military population means systematic bloodwork, laboratory capacity, electronic health record integration, and data governance for a biomarker that intersects with fertility, mental health, and chronic disease. The Defense Health Agency, which operates the military's MHS Genesis electronic health record system, will presumably handle the clinical data pipeline. How deficiency notifications, treatment opt-ins, and longitudinal tracking flow through that system has not been detailed in the memorandum itself.